 Since it launched in 2018, Accent Therapeutics has busied itself discovering new targets for cancer drugs in the space of RNA-modifying proteins. But the time for lying low is overjust weeks after the biotech raised a 63 million round, its striking its first Big Pharma partnership with AstraZeneca. 